BioTuesdays

Tag - CompleoTRT

Trimel in pre-NDA meeting with FDA next month

Fresh from reporting positive Phase 3 results for its CompleoTRT intranasal gel for “Low T”, Trimel Pharmaceutics (TSX:TRL) plans to meet with the FDA in February to discuss its plans for filing a new drug application...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.